Know Cancer

or
forgot password

Phase II Study of Oxaliplatin and CPT-11 as First Line Treatment for Extensive Stage Small Cell Lung Cancer


Phase 2
18 Years
N/A
Not Enrolling
Both
Small Cell Lung Cancer

Thank you

Trial Information

Phase II Study of Oxaliplatin and CPT-11 as First Line Treatment for Extensive Stage Small Cell Lung Cancer


Inclusion Criteria:



- Previously untreated extensive small cell lung cancer

- No prior chemotherapy

- No prior radiotherapy except for the treatment of brain metastases

Exclusion Criteria:

- Prior treatment for extensive stage small cell lung cancer

- Known hypersensitivity to any of the components of oxaliplatin or CPT-11

- Greater than grade 2 peripheral neuropathy

- Known HIV or Hepatitis B or C (active, previously treated or both)

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Principal Investigator

Howard (Jack) West, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Swedish Medical Center Cancer Institute

Authority:

United States: Food and Drug Administration

Study ID:

OX-03-099

NCT ID:

NCT00316433

Start Date:

February 2005

Completion Date:

January 2007

Related Keywords:

  • Small Cell Lung Cancer
  • Lung Neoplasms
  • Small Cell Lung Carcinoma

Name

Location
Swedish Medical Center Cancer Institute Seattle, Washington  98104